Paul A. Friedman, Director of Prelude Therapeutics PRLD, has filed 0 purchases and 104 sales on the open market. Over the past 12 months that comes to a net sale of $26.7M. The latest trade was on 06/09.

PF

PF

Paul A. Friedman

Director

Company

Prelude Therapeutics PRLD

First filing

23/01/18

Trades

140 trades

Buys / sales

0 / 104

12-month net buying

−$26.7M

Last trade

06/09

FollowShare

Trading activity

6 months1 year2 years5 yearsAll

Transactions

Company	Trade type	Traded	Filed	Shares	Price	Value	Holding change
Madrigal PharmaceuticalsMDGL	Open-market sale10b5-1 plan	01/09	01/13	24,800 sh29 trades	$522.71avg.	$12,963,319.78	−11.7%
Madrigal PharmaceuticalsMDGL	Open-market sale10b5-1 plan	25/12/10	25/12/12	24,800 sh9 trades	$552.18avg.	$13,694,142.6	−11.7%
Madrigal PharmaceuticalsMDGL	Open-market sale10b5-1 plan	25/08/11–25/08/13	25/08/13	175,980 sh29 trades	$366.27avg.	$64,456,518	−48.5%
Madrigal PharmaceuticalsMDGL	Open-market sale10b5-1 plan	25/07/18	25/07/22	1,400 sh	$350.03	$490,042	−0.7%
Madrigal PharmaceuticalsMDGL	Open-market sale10b5-1 plan	25/07/16–25/07/17	25/07/18	28,876 sh9 trades	$353.19avg.	$10,198,854.62	−13.4%
Madrigal PharmaceuticalsMDGL	Open-market sale10b5-1 plan	24/04/08	24/04/10	26,270 sh7 trades	$246.19avg.	$6,467,480.57	−12.4%
Madrigal PharmaceuticalsMDGL	Open-market sale10b5-1 plan	24/04/03–24/04/05	24/04/05	73,730 sh20 trades	$243.93avg.	$17,984,860.68	−28.4%